1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. XILIO THERAPEUTICS INC
Xilio Therapeutics Inc
XNAS: XLO
Download real time
9.080.03(0.33%)
27.88% Fall from 52W High
8,385
XNAS Volume

XNAS 12 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Xilio Therapeutics Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Xilio Therapeutics Inc share price target, revenues, EPS, net income and more

Xilio Therapeutics Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Xilio Therapeutics Inc Jun-2026 Quarterly Revenue is $19 Million which is growth of 131.2% YoY.

  • POSITIVE

    Quarterly Net Profit Xilio Therapeutics Inc Jun-2026 Quarterly Net Profit is $-6 Million which is growth of 59.8% YoY.

Xilio Therapeutics Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
18.712.713.719.18.12.91.72.32.4
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
22.226.825.52122.516.815.417.11716.518.117.420.1
Operating Profit
-3.5-14.1-11.8-1.9-14.4-13.9-13.6-14.8-14.7-16.5-18.1-17.4-20.1
⌄
-------------
Profit Before Tax
-6.4-9.510.4-16.3-15.8-13.3-13.1-14-13.9-17.2-17.7-16.8-19.4
Tax
-------------
⌄
-6.4-9.510.4-16.3-15.8-13.3-13.1-14-13.9-17.2-17.7-16.8-19.4
Diluted NI Avail to Com Stockholders Ann.
-6.4-9.510.4-16.3-15.8-13.3-13.1-14-13.9-17.2-17.7-16.8-19.4
Basic EPS
-0.3-0.61-1.5-2.2-2.5-2.8-3.1-3.4-8.7-9-8.5-9.8
Diluted EPS After ExtraOrdinary
-0.1-1.2-0.7-0.1-2.2-2.5-2.8-3.1-3.4-8.2-9-8.5-9.8
Number Of Shares End
19.45.810.910.36.95.34.64.54.12222
Net Income Continuing Discontinued Operations
-6.4-9.510.4-16.3-15.8-13.3-13.1-14-13.9-17.2-17.7-16.8-19.4
Normalized Income
-0.8-10.6-4.10.2-14.4-11.7-11.6-12.5-12.4-14.4-15.7-14.9-17.6
Interest Income
-------------
Interest
-------------
Net Interest Income
-------------
EBIT
-6.4-9.510.4-16.3-15.8-13.3-13.1-14-13.9-17.2-17.6-16.8-19.4
EBITDA
-6-9.210.7-16-15.5-12.8-12.7-13.6-13.5-16.8-17.1-16.3-18.9
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
0.30.30.30.30.40.50.40.40.50.40.50.50.5
Profit From Continuing Operations
-6.4-9.510.4-16.3-15.8-13.3-13.1-14-13.9-17.2-17.7-16.8-19.4
Normalized EBITDA
0.8-17.1-32.813.8-13.9-13.4-13.3-14.5-14.2-15.2-17.7-16.9-19.6
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Xilio Therapeutics Inc competitor comparison and performance snapshot within industry

Xilio Therapeutics Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Annual Revenue Xilio Therapeutics Inc Dec-2025 Annual Revenue is $44 Million which is growth of 589.9% YoY.

  • POSITIVE

    Annual Net Profit Xilio Therapeutics Inc Dec-2025 Annual Net Profit is $-35 Million which is growth of 39.8% YoY.

Xilio Therapeutics Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
⌄
-
-
 43.86.3
Cost Of Rev. Ann.
-
-
 -------
Gross Profit Ann.
-
-
 -------
Operating Exp. Ann.
-1.3%
9.5%
95.585.86679.189.27554.619
Operating Profit Ann.
-
-
-31.4-42-59.6-79.1-89.2-75-54.6-19
⌄
-
-
 -------
Other Exp. Ann.
98.1%
-
 71.42.70.9-0.8-0.71.7
PBT Ann.
-
-
-21.8-35-58.2-76.4-88.2-75.8-55.2-17.3
Tax Ann.
-
-
 -------
⌄
-
-
-21.8-35-58.2-76.4-88.2-75.8-55.2-17.3
Diluted NI Avail to Com Stockholders Ann.
-
-
-21.8-35-58.2-76.4-88.2-75.8-55.2-17.3
EPS Ann.
-
-
 -4.2-15.3-38.9-45.1-189.3-29-9.1
Diluted EPS Ann.
-
-
 -4.2-15.3-38.9-45.1-189.3-29-9.1
Number Of Shares End
76%
41.8%
 10.94.62221.9-
Total Exp. Ann.
-1.3%
9.5%
 85.86679.189.27554.619
Net Income Continuing Discontinued Operations Ann.
-
-
-21.8-35-58.2-76.4-88.2-75.8-55.2-17.3
Normalized Income Ann.
-
-
-15.4-33.9-50.9-69-79.8-70.6-53.8-18.9
Interest Income Ann.
-
-
 -------
Interest Ann.
-
-
 -------
EBITDA Ann.
-
-
-20.5-33.5-56.6-73.8-85.6-74.3-54.2-17.1
Reconciled Cost Of Rev. Ann.
-
-
 -------
Reconciled Depr. Ann.
-7.6%
6.4%
1.31.51.61.91.91.51.10.2
Profit From Continuing Operations Ann.
-
-
-21.8-35-58.2-76.4-88.2-75.8-55.2-17.3
Normalized EBITDA Ann.
-
-
-35.3-46.3-57.1-77.2-87.3-73.6-53.5-18.8
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
595.2%
Operating Exp. Ann.
1Y CHG
30%
2Y CAGR
4.1%
3Y CAGR
-1.3%
5Y CAGR
9.5%

Xilio Therapeutics Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Xilio Therapeutics Inc Dec-2025 Total Shareholders Fund is $35 Million which is growth of 100.4% YoY.

  • POSITIVE

    Total Assets Xilio Therapeutics Inc Dec-2025 Total Assets is $155 Million which is growth of 117.6% YoY.

Xilio Therapeutics Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
⌄
3.6%
33.6%
154.771.160.9139.2218.136.362.7
⌄
52.8%
0%
119.453.524.133.532.6119.692.3
⌄
-30.6%
-
35.317.636.8105.7185.4-83.3-29.5
Total Capitalization Ann.
-31.3%
-
35.317.636.8108.8195.1-75.9-19.9
Tangible Assets Ann.
-30.6%
-
35.317.636.8105.7185.4-83.3-29.5
Working Capital Ann.
-4.9%
-
88.83332.2103.4189.7-1.645.9
Invested Capital Ann.
-32.6%
-
35.317.640.1115.5195.1-73.5-19.9
Tangible Book Value Ann.
-30.6%
-
35.317.636.8105.7185.4-83.3-29.5
Borrowings Ann.
-29.4%
-19.9%
78.112.519.920.521.218.6
Net Debt Ann.
-
-
-------
Share Issued Ann.
31%
18.8%
4.53.32221.91.9
Number Of Shares End
76%
41.8%
10.94.62221.9-
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
117.6%
2Y CAGR
59.4%
3Y CAGR
3.6%
5Y CAGR
33.6%
Total Current Liabilities Ann.
1Y CHG
106.2%
2Y CAGR
87.6%
3Y CAGR
38.7%
5Y CAGR
20.5%
Total ShareHolders Funds Ann.
1Y CHG
100.6%
2Y CAGR
-2.1%
3Y CAGR
-30.6%

Xilio Therapeutics Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Xilio Therapeutics Inc Book Value Per Share is $-2 which is growth of -126.3% YoY.

  • NEUTRAL

    ROE Xilio Therapeutics Inc ROE is 0% which is growth of 0% YoY.

Xilio Therapeutics Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
RoA Ann. %
-
-
--88.24%-76.37%-49.39%-59.60%-111.51%-27.60%
ROE Ann. %
-
-
--214.02%-107.25%-60.62%-148.42%--
ROIC %
-
-
--47.5-30.4-16.5-43.7--
OPM Ann. %
-
-
-95.92%-940.18%-----
Inventory Turnover Ratio Ann.
-
-
-------
Asset Turnover Ann. %
-
-
-0.1-----
Working Capital Turnover Ann.
-
-
0.50.2
Quick Ratio Ann.
-
-
-22.85.715.50.99.4
Current Ratio Ann.
-
-
-2.235.915.90.99.8
Interest Coverage Ratio Ann.
-
-
-------
LT Debt To Equity Ann.
-
-
-0.40.20.10.1--
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Xilio Therapeutics Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Cash From Operating Activity Xilio Therapeutics Inc Dec-2025 Cash From Operating Activity is $-5 Million which is growth of 72.8% YoY.

  • POSITIVE

    Net Cash Flow Xilio Therapeutics Inc Dec-2025 Net Cash Flow is $82 Million which is growth of 663.0% YoY.

Xilio Therapeutics Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19
⌄
-
-
-5-18.4-68.6-75.7-80.8-36.1-17.8
⌄
-
-
-0.5-0-0.5-1.9-1.1-2.2-0.7
⌄
-
54.4%
87.829.2-6.6-0.1260.71060
Cash Plus Cash Eqv. End Of Year Ann.
4.5%
46.3%
139.357.146.3122199.620.849
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
82.310.8-75.7-77.7178.8-28.341.5
Cash Plus Cash Eqv. Begin Of Year Ann.
-34.1%
3.1%
57.146.3122199.620.8497.6
Income Tax Paid Supplemental Data Ann.
-
-
-------
Interest Paid Supplemental Data Ann.
-41.5%
-
0.10.60.60.50.50
Capex Ann.
-
-
-0.5-0-0.5-1.9-1.1-2.2-0.7
Issuance Of Capital Stock Ann.
-
32.4%
40.76.8-261.31050.1
Issuance Of Debt Ann.
-
-
---110
Repayment Of Debt Ann.
-
-
-3.4-6.8-0.1-1.1-0.1
Repurchase Of Capital Stock Ann.
-
-
-------
Free Cash Flow Ann.
-
-
-5.5-18.4-69.1-77.6-81.9-38.3-18.6
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
200.7%
5Y CAGR
54.4%
×